How to get successful outcomes with phage therapy: Saima Aslam, MD, MS — Podovirus podcast
54 min

How to get successful outcomes with phage therapy: Saima Aslam, MD, MS

The conversation

Episode notes

Transplant infectious disease physician Saima Aslam shares what treating patients with phage therapy has taught her about choosing cases and judging success. Hear why killing bacteria may not bring lasting improvement, and how clinical experience can shape trials that answer useful questions while fitting into patients’ lives.

Aslam says waits exceeding six months, sometimes reaching a year, pushed her toward patients with chronic infections who could live with their infection while phages were sourced.

All five reported cases of recurrent Pseudomonas bloodstream infection involving cardiac devices failed phage treatment, with complex, longstanding biofilms among Aslam’s proposed explanations.

Her planned trial would randomize 33 female kidney transplant patients with recurrent UTIs to IV phage or placebo, helping distinguish treatment effects from the condition’s natural course.

Episode timeline

  • 0:00 Introduction to Saima Aslam and her clinical experience
  • 4:56 Choosing patients when phage supplies are limited
  • 15:36 Why matched phages failed in cardiac device infections
  • 26:36 Designing trials around the clinical problem
  • 35:56 Planning a controlled trial for recurrent UTIs
  • 47:42 Building a national phage supply and treatment network

Learn more

Transcript

AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.

Select a word or timestamp to listen. Use arrow keys to move between words.

  1. Jessica Sacher

    Hello, welcome to the Podovirus podcast. So we are back, and today we have Dr. Saima Aslam from the University of California San Diego. So she is an MD, professor of medicine, and she leads IPATH, which many are familiar with, the Center for Innovative Phage Applications and Therapeutics. So she's the clinical lead and has treated lots of patients with phage therapy over the years. And, we're so excited to talk to her today about kind of just getting at

    this question we have, which is what's holding back the phage therapy field? Why don't we have it on the shelves everywhere yet? What is really holding things back, and what does it feel like to be on the front lines where you're treating the patients? What's blocking you? So, I'll pass it over to you, Saima, to just give, a bit more background. And we would love to hear about how you got to this point where you're involved in phage therapy.

  2. Saima Aslam

    Okay, yeah, well, thank you very much for the introduction and thank you also for having me on the podcast. So, yes, I treated my first patient with phage therapy in 2017, which, you know, now in 2025, seems like a really long time ago.

    But part of, you know, how I got into it is, you know, being at the right place at the right time. So UCSD or UC San Diego was where the first case of phage therapy in the US was. So, I think we're all aware of Tom's case and Chip Schooley and Steffanie Strathdee, really led that. But for me personally, I'm a transplant infectious disease physician, and within the transplant field in particular, we see a lot of multidrug resistance, and I think, you know, more so than general ID.

    And so there is a really big need for something new and something, you know, that works for multidrug-resistant infections. And so that's how I got into it. The first patient I treated was a lung transplant patient that had been in the ICU for over eight months with just progressively, you know, worse and worse, Pseudomonas pneumonia and ventilator need. So we treated him successfully with phage and eventually he walked out of the hospital.

    And that was something, you know, we weren't sure was going to happen. So since then, at least within UCSD, you know, specifically, we've now treated 21 patients. And I've been involved in a number of other cases at other centers, both in the US as well as internationally. And then we kinda got into clinical trials as well, so at some point I will talk more about that.

  3. Joe Campbell

    So I guess one of the things we usually ask after that is: 2017, so I guess seven or eight years ago was your first case. And I know you've done several. So what do you wish you had known when you were doing your first case that you feel like you now know?

  4. Saima Aslam

    Well, we know a lot more in terms of serum neutralization of phage, and that was unknown then. The patient I treated was immunocompromised, and we treated him twice. So I don't know if serum neutralization played a role in terms of maybe slowing down response to treatment. And, you know, why did we need a second course of phage? Why was one course not enough?

    I think, you know, we know more about phage in terms of some degree of pharmacokinetics. So when I first treated, we had no idea how much to give, how often to give. And so we were just treating it like an antibiotic and giving it every eight hours. We weren't aware of what the concentration of phage should be. And so one of the treatment courses actually had pretty low PFU per mL, and that one we gave every two hours.

    So there were a lot of unknowns and a lot of making up. But I think now we do know more in terms of, you know, how to dose phage and what perhaps is a good concentration of phage to use. When I first started, I was treating for weeks and weeks, and now I'm treating far less. So, yes, I think we have gained enough.

    And I also, I guess I didn't say earlier, when I started off, we were treating anything and everything. In terms of, this is highly drug-resistant, and it's failed, phage therapy. But I think I have a clearer idea now, at least clinically, where I think phage would be beneficial rather than all comers.

  5. Jessica Sacher

    Ah, I feel like this is a pattern. We also interviewed Gina Suh recently and she also said that patient selection, rather than all comers, as you say, has been like, one of the big changes. So how is that? How do you see that now? And what are your criteria when you're gonna accept a patient for phage therapy?

  6. Saima Aslam

    So I think one of the things that's also changed in this time period is that when we first started, it was very new, I mean, it still is, but at that time, there was a lot of interest in a number of academic groups as well as industry to really prioritize patient treatment, so these compassionate use phage therapy programs. Now, with more awareness, there's definitely a lot of interest, you know, everywhere, and the availability of phage that we can use for patients, I think now is very limited.

    And so initially, when you could think of, well, maybe this is a patient I would treat with phage, and you would get phage a month later. Now there is such a long backlog of cases that it takes more than six months, you know, sometimes up to a year to get phage. So if it's going to take that long, then you wanna select for patients that have infections that allow them, you know, to keep living with it.

    So chronic infections like orthopedic or, you know, bone and joint infections. Recurrent UTIs is an area of interest of mine, or recurrent pneumonias. You know, CF population, things like that.

  7. Jessica Sacher

    Got it.

  8. Joe Campbell

    So, how much have you learned? So, I guess now when you get a patient who you think is a good candidate, is it a dose that you always use, or do you use different routes and doses depending on what the patient has?

  9. Saima Aslam

    Yes, I do use a lot of intravenous, so the majority of my experience, actually, all of my patients, except maybe two, I have treated with intravenous phage. You know, some have also received nebulized phage. But in terms of what dose I use, I think most places are now using at least ten to the ninth PFU per mL, or, you know, ten to the tenth. The kind of patients I treat, and again, my focus is more transplant.

    Tend to have systemic infections, and so I have used intravenous. Recently I had a patient that actually had a very sort of rare kind of disorder called malakoplakia. That's where macrophages ingest an organism but are unable to kill it. So you develop this mass, sort of almost like a cancerous lesion, but it's all infection.

  10. Jessica Sacher

    Wow,

  11. Saima Aslam

    And so this was actually a kidney transplant patient with carbapenem-resistant E. coli and malakoplakia. But he had a very large open abdominal wound and he had a huge abdominal mass that came from his kidney. So that patient I treated intravenously, plus topically, plus we actually injected the mass directly with phage as well. So, I think, you know, in terms of how we're giving it really depends on where that infection is.

    So certainly for orthopedic infections, I think locally applying it to the area of infection is key. And most places, you know, would do local application to where the device infection is, as well as intravenous. But I've started using intravenous for sort of shorter and shorter cases because of the development of serum neutralization. Though, I don't know if that truly is playing a role or not in the outcome.

    And you know, perhaps that's why either a shorter course or more local application to the site of infection, you know, may also be effective. But I think these are also unknowns. I mean, we have cases, and you know, this case did great, the one I just talked about. But we kinda hit it from everywhere because we don't know what the best way to treat it was.

  12. Joe Campbell

    Yeah, and then I guess, I mean, it's great for the patient, but I guess then it's one of those situations where you don't know which of any of those was the key one. It could have been that all of them helped, and if you hadn't done any of them… But, you know, this is sort of like maybe why we need to do animal models and clinical trials.

    Because, well, I don't have to explain this

  13. Saima Aslam

    I agree.

  14. Joe Campbell

    to you.

    But yeah, and I guess, in terms of telling patients they're a bad candidate. I guess Jessica and I recently interviewed someone who was a patient and I'm pretty sure he would advocate like, Well, why can't we just give everyone phages? I mean, he may or may not have a more optimistic view of whether the treatment of some of the people you turn down is likely to be effective.

    But I mean, I guess, is it really that you and other people don't have the resources and you have to sort of prioritize? Is it because you want the cases to be successful? How does that sort of break down? And you know, what would it take so that we could just give phage to whoever?

  15. Saima Aslam

    So certainly availability is a big factor, right? That's a huge rate-limiting factor, which makes us, you know, prioritize or somewhat ration phage, right? But one of the things I have learned, there's been a lot of interest in using phage for multidrug-resistant Pseudomonas, cardiac device infections, so LVADs in particular, left ventricular assist devices. So these are devices that are implanted within the heart, unfortunately have a high rate of infection, and one of the things we see is Pseudomonas recurrent bacteremias for weeks and months.

    We published a paper last year in which we describe five cases of this persistent, recurrent Pseudomonas bacteremia with a cardiac device, treated, you know, with various phages, and all of them failed. So that now, you know, we do get those emails, and, I see these patients in clinic too. But without having a single success in that, I don't think that's what we should be treating. So those patients, I do decline, and maybe at some point we will have a treatment.

    But at the moment, you know, it's not going to work. So I don't want to put a scarce resource into something I know is not going to work. So that's sort of an easy no. For others, you know, prioritizing also is, you know, dependent on phage availability, but also the kind of infection. So there's a lot more people working with Pseudomonas phages or Staph aureus and E. coli, less so with Klebsiella or other organisms. So I think that also plays a role in which, you know, we're like, well, maybe I can't help you today, but perhaps we reassess.

    The other thing I'm really trying to do is if there are clinical trials that a patient can go into, then we really recommend that, right? So in particular for cystic fibrosis, there's so many different clinical trials that I don't think we should be treating people on compassionate use, if there's a trial that they fit into. So for myself, you know, also similar for recurrent UTIs.

    There's a Locus study that's ongoing. I'm hoping to start an NIH-funded study for kidney transplant patients with recurrent UTIs over the next few months. So those are people that I keep track of. But I think the biggest limitation really is availability and the delay in getting it, in terms of compassionate use. And I think, and you know, you said this, others have said it too.

    We want to try and get the best outcome possible. So, yes, there's some degree of preselection there.

    Because if we are using it for compassionate use, good outcomes help us get more funding for actually definitive studies. So I think that's something we keep in mind. The other thing I've seen for a number of patients—this was especially true during COVID, when there were a lot of patients on ventilators with drug-resistant Acinetobacter infections. Sometimes the MDR infection is really the tip of the iceberg, or it's more of a, you know, a pointer that this patient is not going to do well.

    And they have many reasons why they're not going to do well, and treating that Acinetobacter is not going to change that. And that's true of many patients also. And so it's hard news to deliver, but treating or eradicating the infection doesn't always, you know, make the patient better. So I think understanding the clinical scenario is very important.

  16. Jessica Sacher

    I really wanna know, who makes the phages that you use currently, or do you get them from a variety of sources?

  17. Saima Aslam

    So I work with everybody. So whoever can help a patient, we work with them. And so that includes, you know, a number of academic collaborators. So Baylor College of Medicine or TAILOR Labs in particular, Daria van Tyne's lab in Pittsburgh, you know, Graham Hatfull in Pittsburgh as well for mycobacterial infections, Texas A&M. I think these are the people I worked most with, and then certainly industry. So that included the, you know, the old days with APT.

    Let's see. BiomX I haven't, but SNIPR Biome, out of Europe, was involved with the patient I treated most recently.

  18. Jessica Sacher

    Oh, cool.

  19. Saima Aslam

    Trying to think who else.

    And, you know, AmpliPhi, again, no longer exists. But the first few cases that I treated were actually with phage from AmpliPhi.

  20. Joe Campbell

    They're now Armata, right?

  21. Saima Aslam

    They are now Armata, yes.

    So Armata has a clinical trial. So we have patients enrolled in that, but we have not used their phage for compassionate use.

  22. Jessica Sacher

    Do you just send out an email to kind of whoever? Is it kind of a mass email every time, like, who can help us?

  23. Saima Aslam

    Not so much, I mean, it used to be mass emails, but now they're more targeted because we know, you know, one person, for example, really has a lot of phages that are ready to go. So E. coli in particular with Baylor, or Pseudomonas, with Daria, I work with Texas A&M, we're working with Burkholderia phages as well, and so they've been wonderful for that. And Klebsiella.

    And then, you know, I think Dr. Hatfull's lab is the only one for M. abscessus phages, so combination there.

  24. Jessica Sacher

    Okay. So it's like stratifying according to species these days.

  25. Saima Aslam

    Yes. Oh, and then UCI as well, I didn't mention. So David Pride at UCSD, and then at UCI we've used Stenotrophomonas phages.

  26. Joe Campbell

    I was just wondering. In the five LVAD cases, you said that you had phages that matched, and could kill in vitro, in the test tube, and then you said you didn't see the desired effect. Do you have any sense? Was it the phages not getting to the bugs? Was it that the phages can't kill in the body because the conditions are different?

    Do you have any idea of what was going on?

  27. Saima Aslam

    Yeah, so we did try to figure out the answer to that. So, you know, we looked at things like, was there surgical debridement or not, you know, sort of clinical factors, but then also phage-related, and, you know, phage, organism-related. So one of the issues with LVAD infections is these infections are very chronic. Most of these patients had had them for months.

    Because of a variety of antibiotic pressures over time, the Pseudomonas biofilm on these phages has a variety of different isolates. So every time when they get bacteremic and we get an organism, that organism is not reflective of that biofilm, right? It's just reflective of the tip.

  28. Joe Campbell

    I see.

    Right.

  29. Saima Aslam

    And so, to me, I think that's a big problem. The other thing, you know, in vitro, when we have biofilm experiments, generally it's like a 24- or 48-hour biofilm, and we use phage and it's great. But that's not true of people with months of complex, you know, biofilm, communities. So to me, I think that's probably one of the reasons.

    So that's one. I do think it gets to where it needs to be because these are intravascular infections. I was talking to somebody actually at a meeting recently, for a very similar patient they had, in which it didn't work either. I mean, two of those patients were not bacteremic when we started phage, but within three to seven days developed bacteremia.

    One patient with septic shock. And I think part of that was release of the organism from the biofilm. I think it's getting to where it needs to be. But I mean, and so again, these are hypotheses. There may be other reasons why it doesn't work. I mean, we looked at antibiotic-phage synergy. You know, all the patients developed serum neutralization at around two weeks. So I mean, was it that when we gave the IV phage after two weeks, it wasn't doing anything?

    I don't know the answer. And we certainly had local phage application as well, and I do want to clarify. So there are case reports of localized device infection without bacteremia, in which you apply local phage and that's been successful, but with the bacteremia ones, I'm unaware of any success.

  30. Jessica Sacher

    Do you have, a good model, or are you incorporating biofilm assays into your phage susceptibility testing at all yet? Or is anybody kind of modeling the biofilm well, as well as you've seen? What are you seeing?

  31. Saima Aslam

    Yeah, so I personally don't have a lab, so I work with people that have labs and I am the clinical sort of piece of that. But yes, I mean, even the patients I talked about with the LVAD infections, not all of them, but at least three of those five, we had tested those Pseudomonas phages specifically against biofilm and showed excellent reduction in biofilm, but again, those are not one-year-long biofilms, But with early onset, yes, and I think most of us are aware of this. And for any, you know, whether it's company or academic group in which we're trying to treat device infections, people are checking, you know, in vitro, like 96-well plate assays, for biofilm activity.

  32. Jessica Sacher

    Yeah. This is kind of delving deep into this one thing, but just curious, is it possible to take some devices out of patients that have surgery? Maybe it's removed, it's not gonna be there, and then use that, like for phage research, like the actual valve or whatever the device is.

  33. Saima Aslam

    I think it can be. That probably would be more possible in the setting of orthopedic infections. I mean, the orthopedic device may come out because we're switching out that, you know, joint and putting a new one in. So I think those, for sure, can be assessed for research purposes, and people have done that with sonication experiments, you know, when patients have infected hips taken out, for example. The LVADs, you know, only come out

    basically after the patient passes away, so that's generally not doable.

  34. Jessica Sacher

    Got it.

  35. Saima Aslam

    Yeah.

    But pacemakers, I think, is another area where that's something that can be looked at, cause those can be changed out when they're infected.

  36. Jessica Sacher

    Yeah. My head is all at this because I've been thinking about this whole P01 grant, which probably you have too, with the phage therapy assay development. And the need for, you know, better models. And I guess, like, my question kind of is becoming like, how do we get a one-year-long biofilm in the lab? Or like, is there a way to make one of those?

  37. Saima Aslam

    I mean, there are ways to make them. Even for LVADs, for example, I've, you know, I've done some of these experiments in the distant past when I was a fellow. The companies can actually provide LVAD material, so that all is very doable in vitro or even in animal implants.

    And that's true, I think for most of these devices. I think, you know, there's so much need for something other than antibiotics that I think when you start making a list of who we should treat, or what I should go after, there’s a million different scenarios, right, based on the organism and the infection. So I feel like for our early stage of where we are in phage research, we should pick sort of the lowest-hanging fruit rather than the hardest ones to go after, right? And then refine, you know, what we know about phages and what we know about how they work clinically in that lowest-hanging fruit. So, and different people may have different ideas of what that is. But I find the recurrent UTI to be, you know, such a niche. And again, it depends on the population with UTIs, but it's, you know, it's very common.

    Patients generally are clinically well, so we're not worried about, you know, someone that's passing away from some underlying disease process. And because it's common, I think in terms of clinical trials, it shouldn't be that hard to enroll.

    So that's one, I mean, the orthopedic infections, I feel like, are very complicated. And for sure there's interest. I mean, there's a company, I think, Phaxiam from France, that's doing a Staph aureus, PJI study as well. But yeah, I think these are lower-hanging ones. I know there's a lot of research in cystic fibrosis as well. I'm not a CF physician. And so, you know, I see it from more of the infectious disease perspective.

    But part of the persistence of those infections is also the underlying architecture of the lung. So I feel like if we're not fixing that, I'm not sure how long-lasting an impact we'll see with phage. And perhaps the goal is reducing flares or reducing need for antibiotics. But We've had patients come to us, with no CF, but a similar disease called chronic bronchiectasis, in which, you know, the Pseudomonas may be the problem at some point.

    But, you know, later in the disease, it's more a symptom of underlying disease, rather than Pseudomonas causing the disease. And so I've treated several of these patients, but I haven't seen any benefit. And that's another one where I don't feel like we should be pushing compassionate use. I think there's a clinical trial by, I think, Armata or another company looking at that, so that probably would be more helpful. But again, if we can't change the disease, I'm not sure treating the infection will help the patient, at least get what they want.

  38. Joe Campbell

    And so in those cases, I guess there's two things. When you say that the treatment hasn't helped, is that based on symptomatic improvement or, you know, how well their lungs work? Are you also monitoring whether you're seeing CFU reduction, and are there cases where you see CFU reduction and it doesn't help the patient clinically?

  39. Saima Aslam

    So, yeah, I had recently a patient, we treated last year, actually. I guess the other thing with compassionate use is they come to us when they're really sick, right? So it's not early in the disease process. So this is somebody that's been on oxygen, supplemental oxygen for years and now has pretty drug-resistant Pseudomonas. So, yes, treating the Pseudomonas and getting subsequent sputum cultures over time, we did see a reduction in CFU. We did not see eradication. Symptomatically, the patient felt better for a little bit. But it's hard to tell if they're truly better or they want to feel better.

    And so it is sort of more of a, you know, a placebo effect. But, you know, after the end of phage, they were kinda back to where they were. It didn't really lead to any lasting reduction. We didn't eradicate the organism. And, you know, they kept on requiring oxygen, which I think they would have anyway, regardless of whether the Pseudomonas was there or not.

  40. Jessica Sacher

    A lot of times when I'm thinking, like, what research is holding back the phage therapy field? And people wanna point to scientific research questions that, if only we answered them, phage therapy would be totally happening. And I increasingly don't think that's where the bottleneck is. I think it's closer to, you know, it's hard to get the resources to do the clinical trials.

    Because there's not really the economics of creating any antimicrobial company in the end, and these antibiotic companies go out of business, so why wouldn't phage companies? Even if they make a great phage cocktail? So where do you see the kind of bottleneck on that spectrum? Or are there, like, still some technical research questions that really we do need to solve that are meaningfully holding things back?

  41. Saima Aslam

    So, I think, you know, it's multifactorial. I don't think there's any one thing. Sometimes I think in the early days in particular, I mean, we did start clinical trials that ended without any meaningful benefit, and I think that was a rush to move into clinical trials.

    Thinking of phage and of the clinical issue as a very sort of 2D, straightforward issue, which they aren't. So I think, yes, there is a lack of resources, but the NIH has started putting money in it, right? So they funded a couple of clinical trials and now we have these large center trials also coming out. And there are a number of companies that have come and gone also within phage therapy.

    So I think we need to learn more about how they work best. And, you know, I don't think we can use phage as if it were equivalent to an antibiotic and do such an in vitro study and say, okay, let's treat the patient.

    There are a number of reasons for that. So I feel like we do need more in vitro, we do need more animal model stuff. That being said, you know, there's a role for the compassionate use. And there's some areas where I think clearly we have enough information that we can do clinical trials. So it goes back to that UTI, you know, couple of trials in that setting.

    I think it's also important to really understand the clinical scenario. So some of the companies I've seen start trials, um, have done so because they know the phage piece really well, but they haven't really researched that clinical piece well.

    And I think that's a big reason why some of these studies have failed.

    And even though I've said UTI, I mean, you know, there was a large study, that was published, from Europe, right, looking at, prostate surgery and using phage in that setting, but clinically, to me, and this again, you know, I don't mean any negative things for other clinicians, but I feel like there needs to be greater collaboration between the phage research piece and the clinical piece, because some of it doesn't match. So that UTI trial for prostate surgery, as a clinician, I could tell you, just reading the trial protocol, like, why would this work? It wouldn't, right?

  42. Jessica Sacher

    Interesting.

  43. Saima Aslam

    And it didn't. So I think we need stronger collaboration between the two, and I think there is more of that happening now. And that helps both sides understand the issue, because unlike antibiotics, you know, phages don't do indiscriminate killing, right? Which is sort of the easier, straightforward thing. Phage is so much more specific. Yeah, so I, you know, I think we need greater collaboration between the clinical side and the in vitro or the basic science side for truly translational work.

    And so that, I think, is one issue, at least in terms of the clinical trials so far that have been done, and I think that is changing. But, you know, the other thing is also going back to that picking lower-hanging fruit. I think if we work collaboratively, if we can show it works in one thing, then we certainly will have a lot more money to figure out how it works in something else, right?

    And then it's more complicated than using an antibiotic to treat a patient because phage is so specific. There is the human response, you know, the immune response to phage that we don't see with antibiotics. And I think these things play a role.

  44. Joe Campbell

    Yeah, I mean, I think you're absolutely spot on. I mean, having listened to, in various forums, companies talk about clinical trials, I think exactly what you said, you know, talking to the clinicians and getting really detailed ideas about which endpoints you're gonna select, is really paramount for success. Because, you know, obviously, if you're gonna do a twelve-week trial, you don't wanna be picking an endpoint that your clinician will tell you,

    “Well, even when an antibiotic works really well, you don't really see that endpoint met very often until 24 weeks.” And then you set up your phage, you're basically setting it up for failure.

  45. Saima Aslam

    Yes.

  46. Joe Campbell

    And I think that's something that sort of, naively, I didn't realize how important that was. And once you start thinking about it's kind of more obvious. But it's one of those things that I think a lot of phage companies, they get so jazzed on their phage and, you know, how well it can kill and blah, blah, blah.

    All those things are really important.

  47. Saima Aslam

    Yes.

  48. Joe Campbell

    But they get so excited with that. They don't bother to think about, you know, what the clinicians would tell them about what's realistic and what isn't. So I think that's, you know, it's great that, I know you're working with a lot of phage biologists, and, you know, it's important that people sort of understand each other, understand what they can learn from each other.

  49. Saima Aslam

    Yes, so I think, you know, that degree of mutual respect certainly is needed. I think it is there now. I don't know if it was there always. But we need to kind of collaborate on both sides of that equation, I think, and we are now, yeah.

  50. Joe Campbell

    And without asking you to cast aspersions on anyone. I mean, I guess I'm a little bit curious. There was a paper published by the group from Belgium recently with like 100 patients that they treated. And I'm sure you're familiar with that. And I mean, I guess without again casting aspersions, are there patients that you said, “Oh, I wouldn't have ever thought to treat”?

    Do you think they're treating people where it's not likely to be successful? Or what was your reaction to the patient list?

  51. Saima Aslam

    I haven't looked at it recently, but from what I remember, a lot of it was respiratory infections, including otitis media stuff, and it said upper respiratory. Yeah, I don't think there was that much detail regarding patient clinical scenarios, but rather big syndromes. So the otitis media type stuff, I think, is used more in Europe because it is freely available to treat, you know, anything.

    But they certainly had cases of, you know, bone and joint infections. I think they had bacteremias and things like that also. But the biggest chunk that I remember was upper respiratory, but I forget the exact percent.

  52. Jessica Sacher

    That's interesting. So, it's not so much the entire syndrome that might preclude phage from working in your prediction. But it would be more like case by case, like that patient and that scenario. Like, what level of resolution do you kind of need to see as a clinician to gauge if it’s a go?

  53. Saima Aslam

    I think the organism and the clinical syndrome. Yeah.

  54. Jessica Sacher

    Okay, so you don't need, like, that specific patient type.

  55. Saima Aslam

    As far as I know. You know, we're all learning.

    Yeah, but I mean, for example, at our center, we have, you know, a very careful patient selection process for phage.

    And we've had really good success rates. It's a smaller number of patients, you know, 21 thus far, locally, and our outcomes are like an 85 percent success rate. So the ones that didn't work are the ones I wouldn't treat anymore. This would be the LVAD bacteremias and then chronic bronchiectasis as well. I don't think we can, you know, help patients when they're late stage.

    So those were our biggest failures.

  56. Joe Campbell

    So with the patients that, you know, fortunately you had success with were there other patients that were similar where you didn't treat them because you couldn't find phages?

  57. Saima Aslam

    So I have not looked at that systematically. I don't know, I mean, certainly for recurrent UTIs, there are patients, I mean, there were some that died while we were finding phages.

    Because, again, the population I look at was kidney transplant. So a UTI in them is not just, you know, a bother. It can lead to sepsis and, you know, all those other thingsum. But there are certainly other patients that, you know, if they make it through a year or so, they get better. So that happens, or maybe we find an antibiotic we're gonna keep them on for the next year and they're okay. But this is not something I've looked at systematically.

    For example, the study that I'm planning to start, hopefully in a couple of months, it's placebo-controlled, so it's recurrent UTIs and kidney transplant patients, and they're all female. You know, we'll do two-to-one randomization, so 66 percent chance you get IV phage, 33 percent chance you get IV placebo. And the reason to do that is to see that natural progression. It's hard to look at historically, but if we are randomizing patients, you know, to placebo versus phage, then hopefully some of these things that are inherent, you know, that impact the outcome are equal in both arms. But we'll see.

  58. Jessica Sacher

    How many patients do you need to recruit for that study?

  59. Saima Aslam

    33.

    It's a small study. It'll be cool. I'm excited about it.

  60. Joe Campbell

    And just sort of getting into the funding geekery, but as I recall, you're getting funded by the kidney institute?

  61. Saima Aslam

    Yeah, NIDDK.

  62. Joe Campbell

    Not NIAID. So Jessica interviewed me a while ago, about, you know, NIAID and how funding. And one of the things I was saying is that it seems like other, institutes are now also starting to be willing to fund this.

    I mean, we talked a little bit about this, you and I, when you were applying, but did you find that the study section was receptive to the idea of phages?

  63. Saima Aslam

    Part of the study section was, and part of the study section wasn't. We have very strong views, either pro or against, but I guess NIDDK thought it's worth taking a chance on.

    I mean, so recurrent UTIs, and, you know, we specifically focused on kidney transplant because, for a lot of the studies that happen in ID, in particular anything new, immunocompromised patients are always out of it, because we assume they're gonna have bad outcomes. And, you know, for some, maybe they do. And recurrent UTIs and kidney transplant is a huge problem. People lose their kidneys because of recurrent infection, recurrent episodes of rejection, recurrent impact of, you know, pyelonephritis on the kidney tissue. So

    to have waited ten years to get a kidney transplant and then you get recurrent UTIs and you lose it in two years is awful. It's just terrible. And a lot of these people lose their kidneys very quickly. If you don't have recurrent UTIs, your kidney's good for the next ten years. So it has a huge clinical impact. We may not necessarily see that whole, you know, impact within the small pilot study, but I think they understood that this is a big problem. No one's really working on it. All the trials on recurrent UTIs are looking at antimicrobial stewardship. That's not helping the patient. So I think I made a very emphatic case that this is worth doing.

    And I strongly believe it is. So, I guess, you know, they were interested. They're the kidney center and they want the kidneys to be good.

  64. Jessica Sacher

    Yeah, that's great. So antibiotics don't work in that population?

  65. Saima Aslam

    They do. For kidney transplant patients, and I'm talking more about females here because it's more common in women. Certainly, men have it too. Generally, when they have, for example, an E. coli UTI, I could treat it and they'll get better, but they'll have another episode two months later.

    Usually the time between them getting sick and landing up in the ICU is very short. So we've had people die of pan-susceptible E. coli sepsis because they become sick so rapidly because their immune system's not working.

    We can keep treating the UTIs, and it's all treatable for some patients, but each time they get a UTI, it's an insult to that kidney, so they're losing bits of kidney each time. Certainly, with recurrent, treatment or recurrent antibiotics, there's a much higher rate of drug resistance. So ESBL, for example, is very common when you look at different centers. The percentage of ESBL among their kidney transplant population can be anywhere from 40 to 80 percent. So then you have recurrent UTI patients in which all you can treat them with is an IV antibiotic. So I actually now keep ertapenem in my clinic because you can give it intramuscularly. During COVID, I had a lady who had a PICC line for two years and she had a bag of ertapenem in her fridge.

    So that when she had a UTI, I told her to start, cause her hospital was full. There's no place for her to come in, so there are multiple reasons of why it's sort of a big, bad problem. So I think, you know, and I'm hoping phage works. You know, I don't know if it will, but that's our goal.

  66. Jessica Sacher

    And do you think phage will lead to less problems with recurrence, or do you have reason to believe that?

  67. Saima Aslam

    So I've treated, and this is a very small N. I've treated three patients, with recurrent UTIs. Two of them had ESBL E. coli, one had ESBL Klebsiella, with a, you know, UTI frequency of almost one a month. For a couple of them. I treated all three with phage when they were not sick. So there's some data showing, you know, the E. coli that we carry in our gut is what's causing the infections. And all of them had ESBLs, so we targeted the ESBLs, and treated, you know, three of these.

    when they were asymptomatic, so we're really treating their carriage, right, or their colonization.

    And all three of them went a year at least out afterwards with no recurrence.

    And when one of them finally did have a UTI, it was not the ESBL we targeted.

    So it was pretty dramatic.

    And again, you know, these are preselected patients. And again, that's why we're doing a placebo-controlled study, right? So maybe those three are not the norm, I don't know, but I think, you know, it's worth looking at. And that's where the money is needed, right? So, I mean, some things, it's one of those high-risk, high-reward things. If it works, this is amazing. If it doesn't, that's fine. We did a 30-patient trial. We know and we move on. But without having that initial investment, you can't answer that question.

  68. Jessica Sacher

    Yeah. So do you think every physician that's going to write a trial protocol for phage should have already treated, like, a bunch of patients compassionately for them to kind of be in a position to make these decisions?

  69. Saima Aslam

    I mean, I think whoever is writing that clinical trial protocol, yes, should be in close collaboration if they are not the person treating these patients, right?

    Because then, you know, sort of the nitty gritty of how am I giving phage to this patient? How am I working with the pharmacy to make this happen? So my patients, they self-inject at home. I teach them how to do it. The NIH, you know, that was a big, hard pill for them to swallow. Well, how do you know they're giving themselves their medication if you're not seeing them every day? I'm a very strong proponent of sort of looking at things from the patient perspective. To me, it didn't make sense that I have someone coming into an infusion center twice a day to give an IV they could do at home.

    So we had a workaround. We're gonna do video visits with them and we'll see them give their IV, so we know it's done and they do it at home.

    So, yeah, I think having the experience is helpful to design a trial that is, you know, pragmatic. In some studies, people think of the patients as sort of how they would treat, you know, their lab animals, right? They're there to take lots of blood draws and all that kind of stuff and multiple visits. Those studies are hard to enroll for. I mean, patients all have their own lives, too.

    So I think it's helpful to have somebody that works with patients and has worked with phage as part of that planning process.

  70. Jessica Sacher

    Yeah, you wanna take it to the future-looking questions now, Joe?

  71. Joe Campbell

    Yeah, I guess. This is sort of the point where we usually ask, you know, where do you hope to be in five years? Where do you hope to be in 15 years? And I guess what might keep you from getting there? What worries you about that?

  72. Saima Aslam

    So, well, five years, I'm hoping everyone with a kidney transplant with recurrent UTIs can get phage and it takes care of their problem. I think that would be amazing. And maybe in ten years we're doing bigger, definitive, you know, phase three trials, or maybe it's not needed. So yeah, five years, I really am hopeful that at least for this one indication that I'm looking at, it's going to work and we're gonna have it available to people. Greater than that. I mean, I'm also

    working with the Cystic Fibrosis Foundation for developing, Burkholderia phage therapy for CF and lung transplant patients. So I think by then, I mean, ten years is too far out. That probably is five years, also that we're doing that study, and maybe it's done, I think, ten to 15 years. I feel like by then either phage is available and it worked, or if it hasn't, then I'm not sure it's going to.

    So I feel like this coming decade where we have enough knowledge to design good trials, is gonna either make it, or if we have multiple failed trials, then that's the end of it.

  73. Jessica Sacher

    Yeah, I like that, like a go/no-go decision. And it really does feel like of all the trials that have been completed and published, most of them seem like they failed for design reasons, not phage reasons necessarily, or they weren't a fair assessment of the phage itself. So we still don't have the answer, even though there have been trials. So now hopefully we can get the next batch of trials…

  74. Saima Aslam

    I think people are really making that concerted effort. Like, instead of it being a race of me first, me first, it's more, let's take a breath and let's think this through before we get going. And I think that's the way to do it. We wanted to give it, you know, our best chance of it working.

  75. Joe Campbell

    Yeah, I think certainly companies are more and more appreciating that. You know, you don't want to get the reputation of having a failed trial, cause that's gonna send the investors running for the hills.

  76. Saima Aslam

    So the recent PJI study that ended, it ended with zero enrollment, so it failed because they couldn't enroll anyone, because it was just too complicated and not pragmatic. And that's not necessarily shade on the phage, right? That's again sort of a clinical trial design issue.

  77. Joe Campbell

    So I have a further question. And I think you and Gina and others have kicked around the idea of having sort of a U.S. depository of phages. And trying to get, you know, whatever, the usual people you get phages from to contribute. And I guess I've had discussions, and maybe they're not really gonna come to anything. Because now who knows what's gonna happen with the NIH Clinical Center. But, you know, like, what would be involved in that?

    Where could you imagine it being housed? And like, how much would it cost, if the government was gonna make an investment in that, or someone was gonna give a chunk of change? What do you think would be involved in having, you know, a countrywide phage repository, sort of like what they have in Australia or something?

  78. Saima Aslam

    I mean, I've tried getting funding for that a few different times. It hasn't happened.

    But I think, you know, as the compassionate use cases show, there is a certain population of patients that really do benefit from phage. Whether they're part of clinical trials or not, you know, remains to be seen. So I think one, manufacturing is a big hurdle, right? So we need at least one manufacturing site for the country.

    If there are certain phages that have been used over and over again in patients and we know they work, so it'd be great to have these set up. I think it's helpful to just have a few sites where phage is given. So patients can travel to such a site and get phage therapy, and, you know, obviously in different parts of the country, so it's not hard to get to. That way, those centers have and develop further expertise in the clinical application of it, and then we get away from the current lag time of six months to a year.

    In terms of cost, I mean, part of it is really the initial investment to set up a manufacturing facility. I think that's a big hurdle. The clinical piece of it really is not that expensive. So I don't manufacture phage, so I don't want to give a number that's going to be erroneous and too low.

  79. Joe Campbell

    That's fine.

  80. Saima Aslam

    Yeah, but I think, you know, if we had a couple of well-to-do donors, I feel like something could be done.

  81. Joe Campbell

    Yeah, I mean, I was well, before we started this interview, I mentioned I was in Pittsburgh and I was talking to Daria a little bit about this. And I did have some conversations at some point about, I think, introducing you and Gina to some of the people I know at the NIH Clinical Center. And they had some interest. And obviously, right now we don't know what, if anything, they'll be able to do.

    But, you know, there was some interest. And I guess I'm wondering if we should try to, like, convene a meeting of the minds and see…

  82. Saima Aslam

    That would be wonderful because I think there are people that benefit. And all of our centers, you know, we see these case reports, and all these other countries have managed to do this. So It's kinda sad that we don't have that in the U.S., and it's sort of each center for themselves.

  83. Joe Campbell

    right.

  84. Saima Aslam

    But there's a better way to do it, right?

  85. Joe Campbell

    Yeah, I mean, I know with some of the companies, they have some concern that if their phages are used compassionately, and, you know, there were some safety signals, they're worried that their clinical trial will be put on hold. And, you know, it's not that they don't want to help people, but, you know, obviously that's a potential issue.

  86. Saima Aslam

    Yeah, no, I understand that, but I think, you know, within, for example, we have all these different labs, right? You mentioned Daria, there's TAILOR Labs, you know, Stanford, UCSD, all these places, or Mayo. I mean, I think there's a way that the academic labs can work together with a central manufacturing site.

    They're doing that already, but they're doing that all, you know, one-on-one, which slows things down. But I think if there's a funded central site where it's being manufactured and you have people that know what they're doing, doing the treating part, we probably could treat more patients, maybe with better outcomes.

  87. Jessica Sacher

    Yeah. We’ll probably get to wrapping this up. But I just had a thought on your clinical trial that you've got going. So do you have plans to spin that out into a company if it goes well? And do you think it'll be like a cocktail you're using on each patient that you might be able to land on, or will it be kind of the individualized approach, um?

  88. Saima Aslam

    So it's not an individualized approach. I'm working with Baylor College of Medicine, so Anthony Maresso and his group. So we decided initially to start off sort of, you know, individualizing. But we realized that three of their phages covered like 75 percent of my patients’ isolates.

    And in terms of INDs, and in terms of phage delivery and being efficient, it made sense to use that. So, in the end, we decided to do a three-phage cocktail.

    So those three phages come from Anthony's lab. I know Baylor has formed a company, PHIOGEN.

    And so, yeah, that's not me spinning off a company, but I think it's possible. Yes.

  89. Jessica Sacher

    Cool, awesome.

    We interviewed, the team at PHIOGEN. That one's not out yet. It's in my editing backlog, as this one will join it.

    But it'll be really cool to have, yeah, the perspectives beside each other. And this has been so enlightening. Thank you so much for being here and giving us a window into your side. I've got so many little nuggets that I didn't have before. That's really cool.

  90. Joe Campbell

    Yeah, no. Thank you for taking the time and thank you as always. I mean, it's great. You clearly think so hard and carefully about these things and it's a credit to you. And well, you know, it's just wonderful.

  91. Saima Aslam

    Thank you very much. It was a pleasure talking to both of you.

  92. Jessica Sacher

    Yeah, see you around.

  93. Joe Campbell

    All right.

  94. Saima Aslam

    Take care.

  95. Joe Campbell

    Bye.